443,373 Shares in Kenvue Inc. $KVUE Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 443,373 shares of the company’s stock, valued at approximately $8,473,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Elyxium Wealth LLC bought a new position in shares of Kenvue during the 4th quarter worth approximately $26,000. Johnson Financial Group Inc. purchased a new position in shares of Kenvue in the second quarter worth $26,000. MV Capital Management Inc. purchased a new position in Kenvue in the 4th quarter worth $28,000. CoreCap Advisors LLC raised its stake in shares of Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the last quarter. Finally, Reflection Asset Management purchased a new position in Kenvue during the 4th quarter worth approximately $32,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KVUE has been the subject of a number of analyst reports. UBS Group decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Barclays raised their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.27.

Kenvue Stock Performance

NYSE KVUE opened at $19.23 on Thursday. The stock has a fifty day simple moving average of $19.12 and a 200-day simple moving average of $18.23. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The stock has a market cap of $36.94 billion, a PE ratio of 22.10, a P/E/G ratio of 1.38 and a beta of 0.47. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $20.95.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 earnings per share. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th were issued a $0.21 dividend. The ex-dividend date was Wednesday, August 12th. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.